Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Ups Vidaza Discount To Gain Positive NICE Recommendation

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. cost-watchdog NICE recommends reimbursement for Celgene's Vidaza after the company offers a steeper discount.
Advertisement

Related Content

Italy Leads European Push Into Conditional Reimbursement
Italy Leads European Push Into Conditional Reimbursement
GlaxoSmithKline’s Votrient Recommended For Renal Cell Carcinoma in Draft NICE Appraisal
UK Value-Based Pricing Proposals Aim To Increase Access, Broaden Assessment of Drug Benefits
NICE Likely To Lose Cost-Watchdog Status By 2013
NICE Rejects Vidaza, But Celgene Plans Comparator-Based Appeal
NICE Rejects Vidaza, But Celgene Plans Comparator-Based Appeal
Celgene Gains Hematology And Oncology Muscle With Pharmion Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS071842

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel